NCT03229291View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 3, 2016

Primary Completion Date

June 11, 2017

Study Completion Date

June 11, 2017

Conditions
Tendinopathy
Interventions
DRUG

SM04755

SM04755 is a small molecule inhibitor of the Wnt pathway.

DRUG

Vehicle

Same formulation as topical SM04755 solution, without SM04755 included.

Trial Locations (1)

85283

Research Site, Tempe

Sponsors
All Listed Sponsors
lead

Biosplice Therapeutics, Inc.

INDUSTRY